This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== July === July 1 Recreational cannabis becomes legal in Connecticut and Virginia. Medical cannabis becomes legal in South Dakota. COVID-19 vaccination – Michigan Governor Gretchen Whitmer announces a month-long vaccination raffle in which residents can win a total of $5 million in cash (one grand prize of $2 million or three prizes of $1 million) and $500,000 total in college scholarships for children ages 12–17 years old (nine prizes of $55,000). The winners were drawn on August 4. July 2 – Hundreds of businesses are hit by a large-scale cyberattack, linked to the Russian REvil ransomware gang. July 2–5 – At least 233 people were killed and 618 people were injured in over 500 shootings nationwide during the Independence Day weekend. July 6 – 2021 New York City mayoral election – Eric Adams was declared the winner of the Democratic primary for mayor of New York City. July 7 – The Tampa Bay Lightning defeat the Montreal Canadiens (4-1) in the 2021 Stanley Cup Finals to win their second consecutive Stanley Cup. July 8 – Attorney Michael Avenatti is sentenced to 2.5 years in prison for attempting to extort Nike. July 9 Twitter suspensions – Twitter announces that they have suspended political commentator and nationalist Nick Fuentes. President Biden signs a 72-point executive order placing tighter regulations and scrutiny on major corporations in a variety of sectors, including Big Tech companies.
In contrast to the general similarity in structure and function of the electron transport chains in eukaryotes, bacteria and archaea possess a large variety of electron-transfer enzymes. These use an equally wide set of chemicals as substrates. In common with eukaryotes, prokaryotic electron transport uses the energy released from the oxidation of a substrate to pump ions across a membrane and generate an electrochemical gradient. For bacteria, oxidative phosphorylation is understood in most detail in Escherichia coli, while archaeal systems are, at present, poorly understood. The main difference between eukaryotic and prokaryotic oxidative phosphorylation is that bacteria and archaea use many different substances to donate or accept electrons. This allows prokaryotes to grow under a wide variety of environmental conditions. In E. coli, for example, oxidative phosphorylation can be driven by a large number of pairs of reducing agents and oxidizing agents, which are listed below. The midpoint potential of a chemical measures how much energy is released when it is oxidized or reduced, with reducing agents having negative potentials and oxidizing agents positive potentials.
Major cities and regional rivalry played an important role in the wars. The disappearance of a central, imperial authority—and in some cases of even a local, viceregal authority (as in the cases of New Granada and Río de la Plata)—initiated a prolonged period of balkanization in many regions of Spanish America. It was not clear which political units should replace the empire, and there were no new national identities to replace the traditional sense of being Spaniards. The original juntas of 1810 appealed first to a sense of being Spanish, which was counterposed to the French threat; second, to a general American identity, which was counterposed to the Peninsula lost to the French; and third, to a sense of belonging to the major cities or local province, the patria in Spanish. More often than not, juntas sought to maintain a province's independence from the capital of the former viceroyalty or captaincy general as much as from the Peninsula itself. Armed conflicts broke out between the provinces over the question of whether some cities or provinces were to be subordinate to others as they had been under the crown. This phenomenon was particularly evident in South America. This rivalry also led some regions to adopt the opposite political cause to that chosen by their rivals. Peru seems to have remained strongly royalist in large part because of its rivalry with Río de la Plata, to which it had lost control of Upper Peru when the latter was elevated to a viceroyalty in 1776.
The metal is produced electrolytically from a mixture of fused lithium chloride and potassium chloride. Sodium occurs mostly in seawater and dried seabed, but is now produced through electrolysis of sodium chloride by lowering the melting point of the substance to below 700 °C through the use of a Downs cell. Extremely pure sodium can be produced through the thermal decomposition of sodium azide. Potassium occurs in many minerals, such as sylvite (potassium chloride). Previously, potassium was generally made from the electrolysis of potassium chloride or potassium hydroxide, found extensively in places such as Canada, Russia, Belarus, Germany, Israel, United States, and Jordan, in a method similar to how sodium was produced in the late 1800s and early 1900s. It can also be produced from seawater. However, these methods are problematic because the potassium metal tends to dissolve in its molten chloride and vaporises significantly at the operating temperatures, potentially forming the explosive superoxide. As a result, pure potassium metal is now produced by reducing molten potassium chloride with sodium metal at 850 °C.
In 2007, the Alcohol and Tobacco Tax and Trade Bureau (TTB) effectively lifted the long-standing absinthe ban, and it has since approved many brands for sale in the US market. This was made possible partly through the TTB's clarification of the Food and Drug Administration's (FDA) thujone content regulations, which specify that finished food and beverages that contain Artemisia species must be thujone-free. In this context, the TTB considers a product thujone-free if the thujone content is less than 10 ppm (equal to 10 mg/kg). This is verified through the use of gas chromatography–mass spectrometry. The brands Kübler and Lucid and their lawyers did most of the work to get absinthe legalized in the U.S., over the 2004–2007 time period. In the U.S., 5 March sometimes is referred to as "National Absinthe Day", as it was the day the 95-year ban on absinthe was finally lifted. The import, distribution, and sale of absinthe are permitted subject to the following restrictions:
Sources: en.wikipedia.org
== Usage == Young's modulus enables the calculation of the change in the dimension of a bar made of an isotropic elastic material under tensile or compressive loads. For instance, it predicts how much a material sample extends under tension or shortens under compression. The Young's modulus directly applies to cases of uniaxial stress; that is, tensile or compressive stress in one direction and no stress in the other directions. Young's modulus is also used in order to predict the deflection that will occur in a statically determinate beam when a load is applied at a point in between the beam's supports. Other elastic calculations usually require the use of one additional elastic property, such as the shear modulus
Kiwis and shorebirds with long bills probe for invertebrates; shorebirds' varied bill lengths and feeding methods result in the separation of ecological niches. Divers, diving ducks, penguins and auks pursue their prey underwater, using their wings or feet for propulsion, while aerial predators such as sulids, kingfishers and terns plunge dive after their prey. Flamingos, three species of prion, and some ducks are filter feeders. Geese and dabbling ducks are primarily grazers. Some species, including frigatebirds, gulls, and skuas, engage in kleptoparasitism, stealing food items from other birds. Kleptoparasitism is thought to be a supplement to food obtained by hunting, rather than a significant part of any species' diet; a study of great frigatebirds stealing from masked boobies estimated that the frigatebirds stole at most 40% of their food and on average stole only 5%. Other birds are scavengers; some of these, like vultures, are specialised carrion eaters, while others, like gulls, corvids, or other birds of prey, are opportunists.
== Gene structure and evolution == The CSP structure is highly flexible. CSPs are characterized by RNA editing and/or post-translational modifications as discovered in the silkworm moth, B. mori [9-14]. The addition of glycine near cysteine at specific location, amino acid inversion and motif insertion in protein sequence strongly argues for the existence of recoding at the level of protein synthesis in the CSP family [9-14]. In addition, they are capable of breathing or specific conformational changes upon ligand binding, which may represent another key feature of the ancestral primitive multifunctional soluble binding protein [15]. The number of CSP genes is usually very low in insects as found in Drosophila flies, Anopheles mosquitoes, Pediculus lice, honeybees and jewel wasps (4-8) [4, 24, 40-41]. A significantly higher number of CSP genes exist in butterfly, moth and beetle genomes (nb CSPs=19-20) [32, 42-43]. Culex mosquito species have between 27 and 83 CSP genes [44]. More than hundreds of protein variants can be produced from CSP genes through or mediated via post-translational modifications and/or RNA-peptide editing as in the case of Dscam and cochlear sensory genes [9-14]. CSP genes evolved via duplication, intron loss and gain, and retrotransposition events [4, 14, 32, 40-41, 45]. A single unified hypothesis of RNA editing and retrotransposition-driven evolution of CSPs, i.e. initial production of new CSP protein motifs via DNA and RNA -dependent RNA polymerization before retro- transposition of edited CSP-RNA variants, has been proposed in moths [11].
=== De novo === De novo synthesis of ceramide begins with the condensation of palmitate and serine to form 3-keto-dihydrosphingosine. This reaction is catalyzed by the enzyme serine palmitoyl transferase and is the rate-limiting step of the pathway. In turn, 3-keto-dihydrosphingosine is reduced to dihydrosphingosine, which is then followed by acylation by the enzyme (dihydro)ceramide synthase to produce dihydroceramide. The final reaction to produce ceramide is catalyzed by dihydroceramide desaturase. De novo synthesis of ceramide occurs in the endoplasmic reticulum. Ceramide is subsequently transported to the Golgi apparatus by either vesicular trafficking or the ceramide transfer protein CERT. Once in the Golgi apparatus, ceramide can be further metabolized to other sphingolipids, such as sphingomyelin and the complex glycosphingolipids.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.